6 terminated. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 3 | 1 | Terminated 1 |
Follow Intercept Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy OCA, Matching Placebo - Biliary Atresia | Phase 2 / Phase 3 | Terminated | Intercept Pharmaceuticals | 28 | 2024-09-02 | 2026-07-07 |
| FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study INT-787, Placebo - Alcohol Associated Hepatitis | Phase 2 | Terminated | Intercept Pharmaceuticals | 67 | 2022-12-15 | 2026-05-05 |
| Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC Obeticholic acid, Bezafibrate 200 MG, OCA Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | Intercept Pharmaceuticals | 75 | 2019-10-02 | 2026-07-16 |
| Obeticholic Acid in Pediatric Subjects With Biliary Atresia OCA 0.1mg, OCA 1.5mg, OCA 5mg - Biliary Atresia | Phase 2 | Terminated | Intercept Pharmaceuticals | 7 | 2015-07-01 | 2023-03-28 |
| Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) Placebo, 10 mg Obeticholic Acid (OCA) - Alcoholic Hepatitis | Phase 2 | Terminated | Naga P. Chalasani | 19 | 2014-11-03 | 2020-01-28 |
| Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) INT-747, Ursodeoxycholic Acid (URSO), Placebo - Liver Cirrhosis, Biliary | Phase 2 | Terminated | Intercept Pharmaceuticals | 165 | 2007-10-01 | 2024-02-06 |
Biliary Atresia (2) · Hepatitis, Alcoholic (2) · Liver Cirrhosis, Biliary (2) · Fibrosis (1) · Hepatitis (1)
obeticholic acid (4) · Bezafibrate (1) · Ursodeoxycholic Acid (1)
France (4) · United Kingdom (4) · Germany (3) · Israel (3) · Netherlands (3) · Spain (3) · United States (3) · Australia (2) · Belgium (2) · Canada (2) · Poland (2) · Austria (1) · China (1) · Croatia (1) · Czechia (1)
Lynda Szczech, MD (2) · David A Shapiro, MD (1) · Lynda Szczech (1) · Naga Chalasani, MD (1)
U01AA021788 (1), U01AA021840 (1), U01AA021883 (1), U01AA021891 (1)